Alltrna is the world’s first tRNA platform company. It involves deciphering the specific functions of various tRNA molecules in the cell and understanding how these molecules interact with other components of the protein synthesis machinery. By gaining insights into the intricate language of tRNA, Alltrna aims to develop innovative therapeutic strategies to target a wide range of diseases.
Alltrna has raised $109 million in Series B financing. The new round included the company’s founder, Flagship Pioneering, and some top-tier investors. The fresh funding will be used to advance Alltrna’s platform and first drug candidates towards the clinic for a first indication in Stop Codon Disease. In total, Alltrna has raised $159 million till that moment.
Alltrna, Cambridge, Massachusetts, United States, was founded in 2018 by Lovisa Afzelius and Theonie Anastassiadis. “The team has made significant advancements to confirm that Alltrna’s platform can turn tRNA’s sophisticated biology into programmable medicines to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation,” said Lovisa Afzelius, an origination partner at Flagship and co-founder of Alltrna.
